RTC
FLGT icon

Riverview Trust Company’s Fulgent Genetics FLGT Stock Holding History

Riverview Trust Company’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-440
Closed -$16.3K – 691
2023
Q2 		$16.3K Buy
+440
New +$15.3K 0.01% 462

Other funds holding FLGT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
DSCM
Divisadero Street Capital Management Miami, Florida $2.39B AUM 134.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Riverview Trust Company's FLGT Position: Q3 2023 in Review

Riverview Trust Company sold out of Fulgent Genetics (FLGT) in Q3 2023, closing a stake of 440 shares — an estimated $16.3K sold.

Riverview Trust Company first reported a position in FLGT in Q2 2023 and held it in 1 quarter. The position peaked at $16.3K in Q2 2023. 201 funds tracked by Wall St. Rank hold FLGT as of Q3 2023.

  • Riverview Trust Company reported no remaining Fulgent Genetics position as of Q3 2023 after selling out during the quarter.
  • Riverview Trust Company sold 440 Fulgent Genetics shares in Q3 2023, an estimated $16.3K.
  • Riverview Trust Company first reported a position in Fulgent Genetics in Q2 2023 and held it in 1 quarter.
  • Riverview Trust Company's Fulgent Genetics position peaked at $16.3K in Q2 2023.
  • 201 funds tracked by Wall St. Rank held Fulgent Genetics as of Q3 2023.

Based on Riverview Trust Company's 13F filing for Q3 2023, filed 17 Oct 2023.